Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study - PubMed (original) (raw)

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study

Peter Ueda et al. BMJ. 2018.

Abstract

Objective: To assess the association between the use of sodium glucose cotransporter 2 (SGLT2) inhibitors and seven serious adverse events of current concern.

Design: Register based cohort study.

Setting: Sweden and Denmark from July 2013 to December 2016.

Participants: A propensity score matched cohort of 17 213 new users of SGLT2 inhibitors (dapagliflozin, 61%; empagliflozin, 38%; canagliflozin, 1%) and 17 213 new users of the active comparator, glucagon-like peptide 1 (GLP1) receptor agonists.

Main outcome measures: The primary outcomes were lower limb amputation, bone fracture, diabetic ketoacidosis, acute kidney injury, serious urinary tract infection, venous thromboembolism, and acute pancreatitis, as identified from hospital records. Hazard ratios and 95% confidence intervals were estimated by using Cox proportional hazards models.

Results: Use of SGLT2 inhibitors, as compared with GLP1 receptor agonists, was associated with an increased risk of lower limb amputation (incidence rate 2.7 v 1.1 events per 1000 person years, hazard ratio 2.32, 95% confidence interval 1.37 to 3.91) and diabetic ketoacidosis (1.3 v 0.6, 2.14, 1.01 to 4.52) but not with bone fracture (15.4 v 13.9, 1.11, 0.93 to 1.33), acute kidney injury (2.3 v 3.2, 0.69, 0.45 to 1.05), serious urinary tract infection (5.4 v 6.0, 0.89, 0.67 to 1.19), venous thromboembolism (4.2 v 4.1, 0.99, 0.71 to 1.38) or acute pancreatitis (1.3 v 1.2, 1.16, 0.64 to 2.12).

Conclusions: In this analysis of nationwide registers from two countries, use of SGLT2 inhibitors, as compared with GLP1 receptor agonists, was associated with an increased risk of lower limb amputation and diabetic ketoacidosis, but not with other serious adverse events of current concern.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi\_disclosure.pdf (available on request from the corresponding author) and have the following declarations: CJ reports personal fees from Pfizer and Bayer outside the submitted work; BE reports personal fees from Amgen, AstraZeneca, Boerhringer Ingelheim, Eli Lilly, Merck Sharp and Dohme, Mundipharma, Navamedic, Novo Nordisk, and RLS Global outside the submitted work, and grants from Sanofi outside the submitted work; and SG reports personal fees and research grants from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp and Dohme, Novo Nordisk, and Sanofi outside of the submitted work. The other authors did not have any potential conflicts to report.

Figures

Fig 1

Fig 1

Flowchart of patient inclusion in the study cohort. SGLT2=sodium glucose cotransporter 2; GLP1=glucagon-like peptide 1. *A patient could be excluded for more than one reason.

Fig 2

Fig 2

Subgroup analyses of serious adverse events among sodium glucose cotransporter 2 (SGLT2) inhibitor users compared with glucagon-like peptide 1 (GLP1) receptor agonist users. P values for homogeneity (all >0.05) are shown in supplementary materials, table 13. *Number of events not specified for <3 according to regulations on reporting Danish register data.

Fig 3

Fig 3

Sensitivity analyses of serious adverse events among sodium glucose cotransporter 2 (SGLT2) inhibitor users compared with glucagon-like peptide 1 (GLP1) receptor agonist users. DPP4=dipeptidyl peptidase 4.

Comment in

Similar articles

Cited by

References

    1. Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;377:644-57. 10.1056/NEJMoa1611925 - DOI - PubMed
    1. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM475487.pdf.
    1. Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes Metab Res Rev 2017;33:e2924. 10.1002/dmrr.2924 - DOI - PMC - PubMed
    1. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). https://www.fda.gov/downloads/Drugs/DrugSafety/UCM506772.pdf
    1. Perlman A, Heyman SN, Matok I, Stokar J, Muszkat M, Szalat A. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database. Nutr Metab Cardiovasc Dis 2017;27:1108-13. 10.1016/j.numecd.2017.10.011 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources